Organization Overview
Timeline
Active Ingredients
Indications
Clinical Trials
Targets and Mechanisms
Alternative names
abt-869 (1 trial)
afatinib (gilotrif) (1 trial)
axitinib (inlyta) (1 trial)
tislelizumab (1 trial)
talazoparib (talzenna) (1 trial)
vitamin e (2 trials)
ipilimumab (yervoy) (1 trial)
Breast Neoplasms (Phase 1)
Endometriosis (Phase 2)
Trials (6 total)
Trial APIs (7 total)